Cancers are often managed through technological advancements with the help of multi-disciplinary cancer conferences where medical oncologists, surgical oncologists, radiation oncologists, pathologists, radiologists and organ specific oncologists meet to find the best possible management for an individual patient considering the physical, social, psychological, emotional and financial status of the patient. Valuable, important updates on behalf of oncologists with respect to the latest advancements in oncology, enables the management of cancer. Clinical trials in respective aspects are very essential for all the patients in whom cancer progresses and for whom no standard of care treatment options are available. In certain circumstances, an oncologist can mean the difference between life and death.
Cancer research enables to identify the causes and to develop strategies for prevention, diagnosis, treatment, and also to improve the performance of clinical trials to evaluate and compare the applications of various cancer treatments.
Subject areas include, but are not restricted to the following fields:
Anticancer Agents, Apoptosis, Biomarkers & Treatment, Cancer Biology, Cancer Informatics, Cancer related Ethics, Cancer Toxicology, Carcinogenesis, Cell, Molecular & Stem Cell Biology, Cellular Oncology, Diagnostics, Drug Discovery & Delivery, Epidemiology & Prevention, Epidemiology and Cancer Prevention, Genetics and Epigenetics, Genetics, Genomics & Proteomics, Immunotherapy, Inflammation & Virology, Kaposi Sarcoma, Leukaemia, Metabolism, Molecular Cancer, Mutagenesis, Myeloma Cells, Oncogenes, Pathology, Predictive Markers, Radiation Oncology, Resistance and Metastasis, Tumour Microenvironment, Tumour Necrosis.
The desire of CPQ Cancer is to publish articles in all related aspects.
Advancements in immunotherapy, particularly immune checkpoint inhibitors, have revolutionized the treatment of metastatic colorectal cancer (mCRC). However, the efficacy of available immunotherapeutic agents is largely limited to tumors with DNA mismatch repair-deficient (dMMR) and/or those with microsatellite instability-high (MSI-H) mCRC. [...] READ MORE
Since being identified as a public health emergency of major international concern, the outbreak of coronavirus disease (COVID-19) in 2019 has rapidly spread globally and has now been declared a pandemic by the World Health Organization (WHO). COVID- 19 has the characteristics of rapid spread from person to person. Many cancer patients often go to the hospital for treatment and disease monitoring. [...] READ MORE
No one predicted what the impact of COVID-19 upon globe would have been. The impact has been devastating, from a humanistic as well as from healthcare perspective. However, I am constantly reminded that no matter where the final numbers tally out to with respect to the human tragedy, COVID-19 thus far is not even close to the Great Flu Epidemic in 1917 during World War I. [...] READ MORE
Next-generation sequencing (NGS) has changed genetic diagnostics due to its high throughput, speed, and cost-effectiveness. This paper describes the challenges that were faced in detection of the frameshift variant c.1175_1214del in the BRCA1 gene, undetectable by CNV analysis, using Oncomine BRCA Research Assay (OBRA) and Ion Torrent platform. [...] READ MORE
Efforts to minimize perioperative blood loss in surgery in order to improve short and long- term outcome should be made, as implications extend considerably beyond the perioperative period. Minimally invasive approaches are associated with less bleeding. [...] READ MORE
Survival of lung cancer patients are affected by many different factors that are extremely variable for each individual. The prognosis of lung cancer primarily depends upon the tumor type, patient immunity and treatment. The objective of our study was to determine the influence of patient symptoms, laboratory findings, imaging modalities and histopathologic tumor features on the prognostic outcome of lung cancer patients. [...] READ MORE
The hormone - dependence of breast cancer has been established for over a century but new investigations in its knowledge have gone away introducing with the step of years. Estrogen and progesterone receptors have been standards for the guide of treatment, but recently waste of cholesterol has emerged as a new perspective for the guide of treatment. [...] READ MORE
Brain metastases (BM) frequently develop in patients with non-small cell lung cancer (NSCLC) with a higher incidence observed in patients with oncogenic driver mutations. Management strategies for BM are rapidly evolving to reflect the advancements in lung cancer biology and the recent application of novel molecular and immunotherapies in NSCLC. [...] READ MORE
Angiogenesis has been suggested as a potential target for anticancer treatment, either by blocking of angiogenic factors production or by blocking of endothelial cell proliferation. The effect of preoperative chemoendocrine therapy is indefinite in the regulation of angiogenic factors, but reports propose that several anticancer drugs have antiangiogenic activity. [...] READ MORE
Cancer is one of the major heterogeneous disease with high morbidity and mortality with poor prognosis. Elevated levels of reactive oxygen species (ROS), alteration in redox balance, and deregulated redox signaling are common hallmarks of cancer progression and resistance to treatment. Mitochondria contribute mainly in the generation of ROS during oxidative phosphorylation. [...] READ MORE